title: Safety of home-based and office allergy immunotherapy: A multicenter prospective study.
abstract: During a 1-year period, 27 otolaryngic allergy practices recorded all systemic reactions to immunotherapy resulting from 635,600 patient visits and 1,144,000 injections. Sixty percent of injections were given at home. Major systemic reactions were observed after 0. 005% of injections. There were no hospitalizations or deaths. Eighty-seven percent of major reactions began within 20 minutes of injection. Frequently observed risk factors for major reactions were buildup phase of immunotherapy, active asthma, and first injection from a treatment vial. Home and office injections had similar rates of total systemic reactions, but home-based immunotherapy had far fewer major reactions. Home-based immunotherapy was found to be safe. The methods and precautions used to treat patients with this degree of safety are specified and discussed.
authors.affiliation: Department of Otolaryngology, Tufts University, and the Department of Immunology, Uppsala University, USA.
authors.forename: D S
authors.initials: DS
authors.lastname: Hurst
authors.forename: B R
authors.initials: BR
authors.lastname: Gordon
authors.forename: J A
authors.initials: JA
authors.lastname: Fornadley
authors.forename: D H
authors.initials: DH
authors.lastname: Hunsaker
mesh_terms: D000328:Adult; D000553:Ambulatory Care; D000707:Anaphylaxis / Q000209:etiology; D002648:Child; D003888:Desensitization, Immunologic / Q000379:methods*; D004305:Dose-Response Relationship, Drug; D005260:Female; D006699:Home Care Services; D006801:Humans; D006968:Hypersensitivity, Delayed / Q000209:etiology; D006969:Hypersensitivity, Immediate / Q000209:etiology; D008297:Male; D011247:Pregnancy; D011446:Prospective Studies; D012130:Respiratory Hypersensitivity / Q000276:immunology / Q000628:therapy*; D012307:Risk Factors; D012646:Self Administration